Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
Status: | Recruiting |
---|---|
Conditions: | Parkinsons Disease |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 11/16/2018 |
Start Date: | March 30, 2017 |
End Date: | April 2019 |
Contact: | Sun Pharma Advanced research company Limited |
Email: | clinical.trials@sparcmail.com |
Phone: | +91 22 6645 5645 |
A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.
This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
Inclusion Criteria:
1. Willing and able to give written, and dated, informed consent (or legally acceptable
representative/impartial witness when applicable) and is available for the entire
study
2. Willing and able to comply with the scheduled visits, treatment plan, laboratory
testing, study procedures, and restrictions (in the Investigator's opinion), and be
accessible for follow-up
3. Male or female aged 18 to 65 years (both inclusive)
4. Diagnosed with Parkinson's disease
Exclusion Criteria:
1. Clinical diagnosis of genetic form of Parkinson's disease, or drug-induced
parkinsonism
2. Diagnosis of Parkinson's disease Dementia (probable, possible)
3. Presence of severe dyskinesias
4. History of brain surgery for Parkinson's disease
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials